Floatz logo

Kyv-101

Multiple Sclerosis

Kyverna TherapeuticsCell therapyPhase 2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
65/ 100

Competitive context

182 Active assets in the Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Cladribine
University Hospital, Strasbourg, France
Phase 4BBB
Nabiximols
Jazz Pharmaceuticals
Phase 4BBB
Teriflunomide
Sanofi
Phase 4BBB
Fampridine
MGH Institute of Health Professions
Phase 4BBB
Ocrevus
Polpharma Biologics International AG
Phase 4BBB

View all 50 →

Same molecule, other indications

Kyv-101 is also rated in:

secondary progressive multiple sclerosisDormant
B
Indicative ·
60 / 100
View asset →
primary progressive multiple sclerosisDormant
B
Indicative ·
60 / 100
View asset →
chronic progressive multiple sclerosisDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →